person · Reporting owner

Webster Stephen W

Disclosed activity across 9 companies

Tapewire entity: 36319
SEC CIK: 0001438421

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cullinan Therapeutics, Inc.CGEM · Entity 4766	Director	June 16, 2026	June 18, 2026
Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180	Director	June 08, 2026	June 11, 2026
Nabriva Therapeutics Legacy plcNBRV · Entity 174291	Director	June 23, 2017	June 28, 2017
Nabriva Therapeutics plcNBRV · Entity 111497	Director	August 02, 2022	August 04, 2022
NextCure, Inc.NXTC · Entity 7461	Director	June 18, 2026	June 22, 2026
Viking Therapeutics, Inc.VKTX · Entity 4067	Director	January 02, 2020	January 04, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cullinan Therapeutics, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.55 · Expires 2026-06-16	Direct	25,319	Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 25,319 · Balance 25,319 F1: The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

Eloxx Pharmaceuticals, Inc.

Report date June 08, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2036-06-08	Direct	13,587	Reported balance After 2026-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-08 · Grant · Acquired 13,587 · Balance 13,587 F1: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Nabriva Therapeutics Legacy plc

Report date June 23, 2017 · Filed June 28, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Expires 2026-08-25	Direct	20,200	Reported balance After 2017-06-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-06-23 · Other · Acquired 20,200 · Balance 20,200 F1: The exercise price is 6.634 Euro. F2: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F3: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016.
Stock OptionSEC Table II · derivative / convertible security · Expires 2026-08-25	Direct	10,100	Reported balance After 2017-06-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-06-23 · Other · Acquired 10,100 · Balance 10,100 F4: The exercise price is 6.634 Euro. F2: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F5: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price is 6.634 Euro.

F2: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.

F3: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016.

F4: The exercise price is 6.634 Euro.

F5: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.

Nabriva Therapeutics plc

Report date August 02, 2022 · Filed August 04, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	11,447	Reported balance After 2022-08-02 transaction · row 1 1 source row Row 1 · 2022-08-02 · Sale · Disposed 7,826 · Balance 11,447 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1900 to $0.1911, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1900 to $0.1911, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

NextCure, Inc.

Report date June 18, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2036-06-17	Direct	2,340	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 2,340 · Balance 2,340 F1: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

Viking Therapeutics, Inc.

Report date January 02, 2020 · Filed January 04, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.95 · Expires 2030-01-02	Direct	22,000	Reported balance After 2020-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-01-02 · Grant · Acquired 22,000 · Balance 22,000

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Gritstone bio, Inc.

Report date April 04, 2025 · Filed April 09, 2025

Section 16 reporting ended · disclosed 2025-04-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-04-04 transaction · row 1 1 source row Row 1 · 2025-04-04 · Other · Disposed 25,000 · Balance 0 F1: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.81 · Expires 2034-04-25	Direct	Reported balance After 2025-04-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-04-04 · Other · Disposed 103,600 · Balance 0 F1: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F2: The option vests as to 1/36th of the total grant monthly beginning May 26, 2024 until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.76 · Expires 2034-06-16	Direct	Reported balance After 2025-04-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-04-04 · Other · Disposed 7,379 · Balance 0 F1: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F3: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value.

F2: The option vests as to 1/36th of the total grant monthly beginning May 26, 2024 until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F3: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date.

Spark Therapeutics, Inc.

Report date December 17, 2019 · Filed December 17, 2019

Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-12-17 transaction · row 1 1 source row Row 1 · 2019-12-17 · Other · Disposed 6,102 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.73 · Expires 2029-01-15	Direct	Reported balance After 2019-12-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-12-17 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.55 · Expires 2028-01-17	Direct	Reported balance After 2019-12-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-12-17 · Disposition to issuer · Disposed 28,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.17 · Expires 2027-01-17	Direct	Reported balance After 2019-12-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-12-17 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.44 · Expires 2026-01-04	Direct	Reported balance After 2019-12-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-12-17 · Disposition to issuer · Disposed 55,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.45 · Expires 2025-03-15	Direct	Reported balance After 2019-12-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-12-17 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-07-07	Direct	Reported balance After 2019-12-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-12-17 · Disposition to issuer · Disposed 106,015 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-12-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-12-17 · Disposition to issuer · Disposed 19,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).

TCR2 THERAPEUTICS INC.

Report date June 01, 2023 · Filed June 01, 2023

Section 16 reporting ended · disclosed 2023-06-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97	Direct	Reported balance After 2023-06-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-01 · Disposition to issuer · Disposed 16,800 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.83	Direct	Reported balance After 2023-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-06-01 · Disposition to issuer · Disposed 12,100 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21	Direct	Reported balance After 2023-06-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-06-01 · Disposition to issuer · Disposed 12,100 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.54	Direct	Reported balance After 2023-06-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-06-01 · Disposition to issuer · Disposed 10,482 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 15, 2019 Filed Jan 18, 2019 02:44 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantRestricted Stock Units · Derivative	10,000	$0.00	$0.00	Disclosure SEC source: 0001609351-19-000013 · wf-form4_154777945875515.xml · derivative · entry 2 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 15, 2020. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 15, 2020. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document
January 15, 2019 Filed Jan 18, 2019 02:44 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantEmployee Stock Option (right to buy) · Derivative	35,000	$0.00 Strike: $42.73	$0.00	Disclosure SEC source: 0001609351-19-000013 · wf-form4_154777945875515.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-01-15 F1 · derivative.exercise_date: 25% vests January 15, 2020 and the remainder vests in equal annual installments over the following three years. Read SEC document
January 02, 2019 Filed Jan 4, 2019 01:28 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantStock Option (Right to Buy) · Derivative	22,000	$0.00 Strike: $8.32	$0.00	Disclosure SEC source: 0001209191-19-001566 · doc4.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-01-02 Read SEC document
May 29, 2018 Filed May 31, 2018 22:59 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	PurchaseCommon Stock, par value $0.00001 per share	8,000	$5.21	$41,712.00	Disclosure SEC source: 0001209191-18-034485 · doc4.xml · nonDerivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.203 to $5.216, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
May 23, 2018 Filed May 24, 2018 00:37 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	PurchaseOrdinary Shares	8,000	$4.59	$36,720.00	Disclosure SEC source: 0001104659-18-035538 · a4.xml · nonDerivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document
May 02, 2018 Filed May 4, 2018 20:01 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	GrantStock Option · Derivative	29,000	$0.00	$0.00	Disclosure SEC source: 0001104659-18-030623 · a4.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Ordinary Shares · 29,000 shares Expires 2028-05-02 F1 · derivative.exercise_price: The exercise price is $4.91 per share. F2 · derivative.exercise_date: This option was granted on May 2, 2018. Vesting began on May 2, 2018 and ends on May 2, 2019. One hundred percent (100%) of the option will vest on May 2, 2019. Read SEC document
January 18, 2018 Filed Jan 23, 2018 00:05 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionRestricted Stock Units · Derivative	1,750	$0.00	$0.00	Disclosure SEC source: 0001609351-18-000015 · wf-form4_151666592504230.xml · derivative · entry 5 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock. F5 · derivative.exercise_date: On January 18, 2017, the reporting person was granted 7,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. F5 · derivative.expiration_date: On January 18, 2017, the reporting person was granted 7,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document
January 18, 2018 Filed Jan 23, 2018 00:05 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantRestricted Stock Units · Derivative	8,000	$0.00	$0.00	Disclosure SEC source: 0001609351-18-000015 · wf-form4_151666592504230.xml · derivative · entry 4 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document
January 18, 2018 Filed Jan 23, 2018 00:05 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantEmployee Stock Option (right to buy) · Derivative	28,000	$0.00 Strike: $50.55	$0.00	Disclosure SEC source: 0001609351-18-000015 · wf-form4_151666592504230.xml · derivative · entry 3 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2028-01-17 F2 · derivative.exercise_date: 25% vests January 18, 2019 and the remainder vests in equal annual installments over the following three years. Read SEC document
January 18, 2018 Filed Jan 23, 2018 00:05 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Tax withholdingCommon Stock	635	$50.55	$32,099.25	Disclosure SEC source: 0001609351-18-000015 · wf-form4_151666592504230.xml · nonDerivative · entry 2 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,615 Read SEC document
January 18, 2018 Filed Jan 23, 2018 00:05 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	1,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001609351-18-000015 · wf-form4_151666592504230.xml · nonDerivative · entry 1 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics common stock. Read SEC document
January 02, 2018 Filed Jan 3, 2018 21:18 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $4.48	$0.00	Disclosure SEC source: 0001209191-18-000858 · doc4.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-02 Read SEC document
November 16, 2017 Filed Nov 20, 2017 22:14 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000120 · wf-form4_151121608406993.xml · derivative · entry 3 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,015 Underlying: Common Stock · 10,000 shares Expires 2024-07-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter. Read SEC document
November 16, 2017 Filed Nov 20, 2017 22:14 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	10,000	$70.14	$701,400.00	Disclosure SEC source: 0001609351-17-000120 · wf-form4_151121608406993.xml · nonDerivative · entry 2 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.95, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
November 16, 2017 Filed Nov 20, 2017 22:14 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	10,000	$3.45	$34,500.00	Disclosure SEC source: 0001609351-17-000120 · wf-form4_151121608406993.xml · nonDerivative · entry 1 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 15, 2017 Filed Sep 20, 2017 01:31 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	GrantStock Option · Derivative	10,100	$0.00	$0.00	Disclosure SEC source: 0001104659-17-057952 · a4.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Underlying: Ordinary Shares · 10,100 shares Expires 2027-09-15 F1 · derivative.exercise_price: The exercise price is $6.86 per share. F2 · derivative.exercise_date: This option was granted on September 15, 2017. Vesting began on September 15, 2017 and ends on September 15, 2018. One hundred percent (100%) of the option will vest on September 15, 2018. Read SEC document
August 15, 2017 Filed Aug 15, 2017 21:05 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000094 · wf-form4_150283110362981.xml · derivative · entry 3 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,015 Underlying: Common Stock · 10,000 shares Expires 2024-07-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter. Read SEC document
August 15, 2017 Filed Aug 15, 2017 21:05 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	10,000	$79.38	$793,800.00	Disclosure SEC source: 0001609351-17-000094 · wf-form4_150283110362981.xml · nonDerivative · entry 2 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.20 to $79.67, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
August 15, 2017 Filed Aug 15, 2017 21:05 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	10,000	$3.45	$34,500.00	Disclosure SEC source: 0001609351-17-000094 · wf-form4_150283110362981.xml · nonDerivative · entry 1 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 31, 2017 Filed Aug 2, 2017 21:58 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	2,337	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000088 · wf-form4_150171109013600.xml · derivative · entry 3 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,015 Underlying: Common Stock · 2,337 shares Expires 2024-07-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter. Read SEC document
July 31, 2017 Filed Aug 2, 2017 21:58 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	2,337	$71.12	$166,207.44	Disclosure SEC source: 0001609351-17-000088 · wf-form4_150171109013600.xml · nonDerivative · entry 2 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017, as amended. Read SEC document
July 31, 2017 Filed Aug 2, 2017 21:58 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	2,337	$3.45	$8,062.65	Disclosure SEC source: 0001609351-17-000088 · wf-form4_150171109013600.xml · nonDerivative · entry 1 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 23, 2017 Filed Jun 28, 2017 01:56 UTC	Nabriva Therapeutics Legacy plc NBRV · Entity 174291	OtherStock Option · Derivative	10,100	$0.00	$0.00	Disclosure SEC source: 0001104659-17-041907 · a4.xml · derivative · entry 2 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Underlying: Ordinary Shares · 10,100 shares Expires 2026-08-25 F4 · derivative.exercise_price: The exercise price is 6.634 Euro. F2 · kind: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F5 · derivative.exercise_date: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017. Read SEC document
June 23, 2017 Filed Jun 28, 2017 01:56 UTC	Nabriva Therapeutics Legacy plc NBRV · Entity 174291	OtherStock Option · Derivative	20,200	$0.00	$0.00	Disclosure SEC source: 0001104659-17-041907 · a4.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,200 Underlying: Ordinary Shares · 20,200 shares Expires 2026-08-25 F1 · derivative.exercise_price: The exercise price is 6.634 Euro. F2 · kind: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F3 · derivative.exercise_date: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016. Read SEC document
June 19, 2017 Filed Jun 21, 2017 20:43 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	7,663	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000060 · wf-form4_149807781707901.xml · derivative · entry 3 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,352 Underlying: Common Stock · 7,663 shares Expires 2024-07-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter. Read SEC document
June 19, 2017 Filed Jun 21, 2017 20:43 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	7,663	$60.00	$459,780.00	Disclosure SEC source: 0001609351-17-000060 · wf-form4_149807781707901.xml · nonDerivative · entry 2 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017. Read SEC document
June 19, 2017 Filed Jun 21, 2017 20:43 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	7,663	$3.45	$26,437.35	Disclosure SEC source: 0001609351-17-000060 · wf-form4_149807781707901.xml · nonDerivative · entry 1 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 25, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	8,102	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000028 · wf-form4_149324327094392.xml · derivative · entry 6 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,015 Underlying: Common Stock · 8,102 shares Expires 2024-07-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter. Read SEC document
April 25, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	8,102	$55.22	$447,392.44	Disclosure SEC source: 0001609351-17-000028 · wf-form4_149324327094392.xml · nonDerivative · entry 4 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27,2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.67, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document
April 25, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	8,102	$3.45	$27,951.90	Disclosure SEC source: 0001609351-17-000028 · wf-form4_149324327094392.xml · nonDerivative · entry 3 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 24, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	1,898	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000028 · wf-form4_149324327094392.xml · derivative · entry 5 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,117 Underlying: Common Stock · 1,898 shares Expires 2024-07-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter. Read SEC document
April 24, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	1,898	$55.00	$104,390.00	Disclosure SEC source: 0001609351-17-000028 · wf-form4_149324327094392.xml · nonDerivative · entry 2 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27,2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.02, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
April 24, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	1,898	$3.45	$6,548.10	Disclosure SEC source: 0001609351-17-000028 · wf-form4_149324327094392.xml · nonDerivative · entry 1 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 18, 2017 Filed Jan 20, 2017 21:04 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantRestricted Stock Units · Derivative	7,000	$0.00	$0.00	Disclosure SEC source: 0001609351-17-000008 · wf-form4_148494627552283.xml · derivative · entry 2 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document
January 18, 2017 Filed Jan 20, 2017 21:04 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantEmployee Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $56.17	$0.00	Disclosure SEC source: 0001609351-17-000008 · wf-form4_148494627552283.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-17 F1 · derivative.exercise_date: 25% vests January 18, 2018 and the remainder vests in equal annual installments over the following three years. Read SEC document
January 03, 2017 Filed Jan 6, 2017 00:16 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $1.19	$0.00	Disclosure SEC source: 0001209191-17-002382 · doc4.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-01-03 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.